Valeant Pharma (NYSE: VRX) filed a presentation related to its conference call on Philidor today. The presentation is embedded below and the following are some highlights from the document:

• Says it has no right to remove CEO and management of Philidor.
• No senior executives, nor board members own a stake in Philidor
• The company hasn't lent any money to Philidor owners.
• The company has the right, but no obligation, to name an advisor to the Philidor CEO
• The company said it recognizes revenue only when products are dispensed
• Third party revenue not recognized when shipped to Philidor
• Revenue recognized and recorded at net realized price
• No evidence of illegal activity at Philidor to-date

Corporate News Insiders' Blog Litigation Trader Talk

Valeant Pharmaceuticals' (VRX) Buy Rating Affirmed at TD SecuritiesOctober 26, 2015 3:33 PM Valeant Pharma (VRX) Halts the Bloodletting Following Conference CallOctober 26, 2015 1:03 PM Valeant (VRX) CC Seen as Step Forward at BMO Capital But More Needed to Rebuild Investor ConfidenceOctober 26, 2015 10:35 AM UPDATE: Valeant Pharma (VRX) Sees Dramatic Red-to-Green Reversal Then Collapses AgainOctober 26, 2015 9:40 AM Mizuho Provides Quick Thoughts on Valeant (VRX) Slides/CallOctober 26, 2015 9:14 AM Valeant Pharma (VRX) says ad hoc committee will review issues brought up in today's WSJOctober 26, 2015 8:43 AM Valeant Pharma (VRX) Regains Some Early Losses as Conference Call StartsOctober 26, 2015 8:09 AM WSJ Highlights More 'Smoke' at Valeant Pharma (VRX) Ahead of Conference CallOctober 26, 2015 6:39 AM Valeant Pharma (VRX) Says Philidor Accounting is AppropriateOctober 26, 2015 6:16 AM Valeant Pharmaceuticals Confirms Appropriateness Of Accounting, Appoints Ad Hoc Board Committee To Review PhilidorOctober 26, 2015 6:15 AM Valeant Pharma (VRX) Adds ValueAct's Morfit as DirectorOctober 26, 2015 6:13 AM Form 10-Q Valeant Pharmaceuticals For: Sep 30October 26, 2015 6:07 AM